Novavax, COVID-19
Make Room, mRNA: What to Know About the Novavax COVID Vaccine
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season.
For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is ‘unfair’
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. t
Canada not ordering Novavax protein-based COVID vaccine this year due to low demand
TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing lack of demand. It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
On the hunt for Novavax: Why people are seeking out the 'traditional' COVID vaccine
Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.
Canada won’t be ordering Novavax’s updated COVID-19 vaccine, cites low demand
The Public Health Agency of Canada says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.
Canadian government not ordering Novavax’s protein-based COVID-19 vaccine this year
TORONTO - The Public Health Agency of Canada says it is not providing Novavax's COVID-19 vaccine this respiratory virus season, citing low demand.
bovnews6h
Novavax Inc (NVAX) Stock: Surpassing Expectations in the Market?
On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $14.42 which represents a decrease of $-0.26 or -1.77% from the prior close of $14.68. The stock opened at $14.07 and touched a ...
Zacks.com on MSN19h
Novavax (NVAX) Dips More Than Broader Market: What You Should Know
Novavax (NVAX) closed at $14.42 in the latest trading session, marking a -1.77% move from the prior day. This change lagged the S&P 500's daily loss of 0.17%. Elsewhere, the Dow saw a downswing of ...
Novavax: Lack Of Sustainable Revenue Growth Is A Problem
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
CNET on MSN12d
What to Know About Novavax, the 'Other' COVID Vaccine
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
Time on MSN11d
Is the Novavax COVID-19 Vaccine Better?
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...
Jefferies Sticks to Their Buy Rating for Novavax (NVAX)
In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...
CBC.ca11d
Moderna's updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not
It is still a thing." Health Canada also approved the protein-based Novavax vaccine (Nuvaxovid) last week. It's designed to target JN.1, which is the dominant lineage in Canada at the moment.
bovnews4d
What’s Fueling Novavax Inc (NVAX) Stock’s 48.65% Gain Above Its 200-Day SMA?
On Friday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.3 which represents a slight increase of $1.15 or 9.47% from the prior close of $12.15. The stock opened at $12.32 and ...
Novavax cools after clarifying analyst report on COVID vaccine market
Novavax (NASDAQ:NVAX) shares fell ~3% in the premarket on Thursday after the company issued a clarification on an analyst ...